-+ 0.00%
-+ 0.00%
-+ 0.00%

SAFI BIOTHERAPEUTICS AWARDED A $4.7 MILLION EXTENSION BY U.S. DOW TO ADVANCE MANUFACTURED RED BLOOD CELLS TOWARD FIRST CLINICAL TRIAL

Reuters·11/03/2026 13:06:12

Please log in to view news